HNWAG
VRTX icon

High Net Worth Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

High Net Worth Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-300
Closed -$66K – 732
2021
Q4 		$66K Buy
+300
New +$58.3K 0.02% 313

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

High Net Worth Advisory Group's VRTX Position: Q1 2022 in Review

High Net Worth Advisory Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 300 shares — an estimated $66K sold.

High Net Worth Advisory Group first reported a position in VRTX in Q4 2021 and held it in 1 quarter. The position peaked at $66K in Q4 2021. 1,071 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

  • High Net Worth Advisory Group reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 300 Vertex Pharmaceuticals shares in Q1 2022, an estimated $66K.
  • High Net Worth Advisory Group first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • High Net Worth Advisory Group's Vertex Pharmaceuticals position peaked at $66K in Q4 2021.
  • 1,071 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on High Net Worth Advisory Group's 13F filing for Q1 2022, filed 13 May 2022.